Menu

Newly Found White Blood Cell Withstands Chemotherapy

Vaccine-induced macrophages open a new realm of study into remodeling the immune system to reduce the risk of infections during cancer treatment.

Jan 1, 2017
Ben Andrew Henry

LAST ONES STANDING: Unlike other immune cells, these vaccine-induced macrophages from a mouse’s lung manage to withstand chemotherapy treatment. ST. JUDE CHILDREN'S RESEARCH HOSPITAL

EDITOR'S CHOICE IN IMMUNOLOGY

The paper
A. Kamei et al., “Exogenous remodeling of lung resident macrophages protects against infectious consequences of bone marrow-suppressive chemotherapy,” PNAS, doi:10.1073/pnas.1607787113, 2016.

Bloodletting
Chemotherapy wipes out cancerous cells and dividing normal cells alike, often particularly damaging those in bone marrow that produce white blood cells. As a patient’s immune system is weakened, even minor infections can become life-threatening. Researchers are exploring ways to circumvent this problem by “remodeling” the immune system prior to chemotherapy.

Below the radar
Akinobu Kamei of St. Jude Children’s Research Hospital and his colleagues identified a class of white blood cell that only becomes active in the lungs of mice following vaccination for a common bacterial strain that causes pneumonia. Like some other immune cells in the lungs, these so-called vaccine-induced macrophages, or ViMs, do not originate in bone marrow, but reside solely in the lungs, likely having derived from progenitor cells in the lungs during embryogenesis.

Survivors
The St. Jude team found that ViMs are not decimated by chemotherapy like other immune cells—in fact, their numbers don’t dip at all. It’s not clear how ViMs manage this feat, says Kamei, but mice that were vaccinated before chemotherapy, triggering ViMs, survived bacterial infections at much higher rates than unvaccinated mice.

Outlook
“The future plan,” says Kamei, “is to induce lung tissue [immune] remodeling to compensate for bone marrow suppression after chemotherapy.” Immunology researcher Sandro Vento of Nazarbayev University in Kazakhstan pointed out in an email to The Scientist that the animal-model work is only preliminary. “This is an initial study which opens a new area of research, and it will be important to understand the mechanisms which allow vaccine-induced macrophages to survive chemotherapy.”

February 2019

Big Storms Brewing

Can forests weather more major hurricanes?

Marketplace

Sponsored Product Updates

Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that its QXDx AutoDG ddPCR System, which uses Bio-Rad’s Droplet Digital PCR technology, and the QXDx BCR-ABL %IS Kit are the industry’s first digital PCR products to receive U.S. Food and Drug Administration (FDA) clearance. Used together, Bio-Rad’s system and kit can precisely and reproducibly monitor molecular response to treatment in patients with chronic myeloid leukemia (CML).
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) today showcases new automation features of its ZE5 Cell Analyzer during the Society for Laboratory Automation and Screening 2019 International Conference and Exhibition (SLAS) in Washington, D.C., February 2–6. These capabilities enable the ZE5 to be used for high-throughput flow cytometry in biomarker discovery and phenotypic screening.
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Researchers to benefit from an innovative software-connected pipetting system, bringing improved reproducibility and traceability of experiments to life-science laboratories.
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Incorporated (NYSE: GLW) will showcase advanced 3D cell culture technologies and workflow solutions for spheroids, organoids, tissue models, and applications including ADME/toxicology at the Society for Laboratory Automation and Screening (SLAS) conference, Feb. 2-6 in Washington, D.C.